Presentación
ONCO-HEMATOLOGY RESEARCH GROUP (HUF)

OncoHematologia_HUF@idipaz.es
Composition
Name
Position
Institution
Juan Guerra Martínez
Jefe de Servicio de Onco-Hematología
Hospital Universitario de Fuenlabrada
Strategic Objective
The main objetive of the group is to translate to the clinic new strategies to treat cancer patients. In particular, we envision that an integrated NGS approach coupled with state-of-the-art molecular and cellular technologies along with newly developed mouse models will help improve the outcome of cancer patients. The group is actively involved in the design of precision oncology strategies as well as immuno-oncology approaches. It is also involved in Clinical Trials to support these strategic research programs.
Research Lines
• Integrating Genomics and Avatar Mouse Models to Personalize Pancreatic Cancer Treatment (ERC-2014-ADG; AVATAR)
• Nanomedicine upscaling for early clinical phases of multimodal cancer therapy (H2020; NoCanTher)
• EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts- EdiREX (EU INFRAIA; EdiREX)
• Regulation of PD1/PDL1 in response to chronic hypoxia induced by antiangiogenic agents
• Inmunotherapy / Inmunotherapy Toxicity